TY - JOUR AU - Lyon, Kristopher A. AU - Huang, Jason H. PY - 2018 TI - Bevacizumab as an adjuvant therapy for glioblastoma in elderly patients: the facts JF - Translational Cancer Research; Vol 7, Supplement 7 (August 28, 2018): Translational Cancer Research Y2 - 2018 KW - N2 - Glioblastoma (GBM) is the most aggressive and common primary brain tumor in adults, recurring in an average of 6.9 months after initial diagnosis even with aggressive treatment (1,2). After initial diagnosis, most patients survive an average of 14 months (3). UR - https://tcr.amegroups.org/article/view/23514